Medina Manuel  Hidalgo net worth and biography

Medina Hidalgo Biography and Net Worth

Director of Guardant Health

Manuel Hidalgo Medina has served as a member of Guardant Health’s board of directors since July 2024. Dr. Hidalgo has served as chief of the division of hematology and medical oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center since 2019 where he oversees clinical and translational research in hematology and medical oncology and is the Walter B. Wriston Professor of Pancreatic Cancer Research. Prior to his current position, Dr. Hidalgo served as chief of the division of hematology at Beth Israel Deaconess Medical Center in Boston and clinical director of the Rosenberg Clinical Cancer Center from 2015 to 2019. During this time, he was the Theodore W. and Evelyn G. Berenson professor of medicine at Harvard Medical School. Dr. Hidalgo also held leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and at the Kimmel Comprehensive Cancer Center, where he was director of gastrointestinal oncology program.


Dr. Hidalgo currently serves as a member of the board of directors of Bristol-Myers Squibb Company. He received his Medical Degree from the University of Navarra in Pamplona, Spain, and a Doctorate in infectious diseases and cancer from the University Autónoma of Madrid, Spain. He completed his Residency training in Medical Oncology at the Hospital 12 de Octubre in Madrid and his Fellowship in Medical Oncology at the University of Texas Health Science Center in San Antonio, Texas, where he also served as an Assistant Professor of Medicine.

What is Medina Manuel Hidalgo's net worth?

The estimated net worth of Medina Manuel Hidalgo is at least $88.44 thousand as of November 7th, 2025. Dr. Hidalgo owns 815 shares of Guardant Health stock worth more than $88,444 as of December 4th. This net worth approximation does not reflect any other investments that Dr. Hidalgo may own. Learn More about Medina Manuel Hidalgo's net worth.

How do I contact Medina Manuel Hidalgo?

The corporate mailing address for Dr. Hidalgo and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Medina Manuel Hidalgo's contact information.

Has Medina Manuel Hidalgo been buying or selling shares of Guardant Health?

In the last ninety days, Medina Manuel Hidalgo has sold $142,785.00 of Guardant Health stock. Most recently, Medina Manuel Hidalgo sold 1,500 shares of the business's stock in a transaction on Friday, November 7th. The shares were sold at an average price of $95.19, for a transaction totalling $142,785.00. Following the completion of the sale, the director now directly owns 815 shares of the company's stock, valued at $77,579.85. Learn More on Medina Manuel Hidalgo's trading history.

Who are Guardant Health's active insiders?

Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.

Are insiders buying or selling shares of Guardant Health?

During the last year, insiders at the sold shares 33 times. They sold a total of 713,670 shares worth more than $42,038,200.84. The most recent insider tranaction occured on December, 1st when insider Terilyn J Monroe sold 55,167 shares worth more than $5,846,046.99. Insiders at Guardant Health own 6.1% of the company. Learn More about insider trades at Guardant Health.

Information on this page was last updated on 12/1/2025.

Medina Manuel Hidalgo Insider Trading History at Guardant Health

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2025Sell1,500$95.19$142,785.00815View SEC Filing Icon  
9/12/2025Sell2,165$54.16$117,256.40851View SEC Filing Icon  
See Full Table

Medina Manuel Hidalgo Buying and Selling Activity at Guardant Health

This chart shows Medina Manuel Hidalgo's buying and selling at Guardant Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Guardant Health Company Overview

Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $108.52
Low: $105.68
High: $109.59

50 Day Range

MA: $83.83
Low: $60.03
High: $111.25

2 Week Range

Now: $108.52
Low: $29.91
High: $112.43

Volume

1,905,484 shs

Average Volume

2,357,725 shs

Market Capitalization

$13.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58